Johnson & Johnson is a healthcare giant selling prescription drugs and medical devices—think medicines for cancer and immunology, plus surgical tools and vision products used in hospitals worldwide.
Money comes from two segments: Innovative Medicine (drugs) and MedTech (devices), with annual revenue of USD 94.19B and a gross margin around 70%, indicating high profitability on patented products.
Decades of patent-protected drugs and entrenched hospital relationships create a durable barrier; competitors like Pfizer and Abbott face high regulatory and R&D costs to replicate J&J's portfolio.
Hold (sector percentile 44) — value B, growth C+, profitability A-, momentum B-, revisions B-. Updated daily, sector-relative, identical for every user.
Key events, in time order
Robotic bronchoscopy system gets AI-powered planning, navigation, and imaging upgrades cleared
M5 mentions JNJ as a defensive blue-chip dividend payer for 2027, but no new facts, only reiteration.
SEC filing shows Aurora bought 1,969 shares of JNJ in Q2
Major leadership shift with implications for Innovative Medicine strategy
Strong new drug sales growth, linked to recent pipeline developments
Settlement may aid resolving talc litigation, pending legal process
FDA approves OTC Tylenol-naproxen combo pill, expanding pain relief portfolio
Q2 beat and FY26 guidance raised, but MedTech miss pressures shares.
Q2 2026 worldwide sales were $25.3 billion, up 5.6% operationally; excluding STELARA headwind of 460 basis points, growth was double digits
None yet
None yet
Johnson & Johnson is a top holding in the iShares Core Dividend Growth ETF, indicating its inclusion in a dividend-focused investment strategy.
Main discussion
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
